

Phone: 661-200-1316 Fax: 661-200-1318

DOB

preopdocs@henrymayo.com

## **Hypoglossal Nerve Stimulation** For the Treatment of Obstructive Sleep Apnea

Patient Name: \_\_\_\_\_

ICD-10-	-CM Diagnosis	Code:		
	G47.33 Obstr	uctive sleep apnea (adult) (pediatric)		
	d Indications			
All of the	the following criteria are met:			
	1.	Beneficiary is 22 years of age or older; Age: and		
	2. Body mass index (BMI) is less than 35 kg/m²; BMI: and			
	3.	3. A polysomnography (PSG) is performed within 24 months of first consultation for HGNS		
		implant; PSG Date: and		
	4.	Beneficiary has predominantly obstructive events (defined as central and mixed apneas		
	less than 25% of the total AHI); Percent of Central and Mixed Apneas: and			
	5. AHI is 15 to 65 events per hour; AHI Events per hour: and			
	6. Beneficiary has documentation that demonstrates CPAP failure (defined as AHI greater			
		than 15 despite CPAP usage) or CPAP intolerance (defined as less than 4 hours per night, 5		
		nights per week or the CPAP has been returned) including shared decision* making that		
		the patient was intolerant of CPAP despite consultation with a sleep		
		expert: CPAP failure/intolerance: and		
	7.	Absence of complete concentric collapse (CCC) at the soft palate level as seen on a drug-		
		induced sleep endoscopy (DISE) procedure; CCC Absence: and		
	8.	No other anatomical findings that would compromise performance of device (e.g., tonsil		
		size 3 or 4 per standardized tonsillar hypertrophy grading scale).		
		Free of compromising anatomical findings:		
Limitat	ions			
The foll	lowing are cor	nsidered not reasonable and necessary and therefore will be denied:		
	1	. Hypoglossal nerve neurostimulation is considered not medically reasonable and		
		necessary for all other indications.		
	2	Non-FDA-approved hypoglossal nerve neurostimulation is considered not medically		
		reasonable and necessary for the treatment of adult obstructive sleep apnea due to		
		insufficient evidence of being safe and effective.		
	3.	. Hypoglossal nerve neurostimulation is considered not medically reasonable and		
		necessary when any of the following contraindications are present:		

a) Beneficiaries with central and mixed apneas that make up more than one-quarter

b) Beneficiaries with an implantable device could experience unintended interaction



of the total AHI.

with the HGNS implant system.



Patient Name: \_\_\_\_\_

Phone: 661-200-1316 Fax: 661-200-1318

\_\_\_\_\_DOB \_\_\_\_\_

preopdocs@henrymayo.com

Page 2 of 2

## Hypoglossal Nerve Stimulation For the Treatment of Obstructive Sleep Apnea

c) BMI equal to or greater than 35

	d)	Neuromuscular disease
	e)	Hypoglossal-nerve palsy
	f)	Severe restrictive or obstructive pulmonary disease
	g)	Moderate-to-severe pulmonary arterial hypertension
	h)	Severe valvular heart disease
	i)	New York Heart Association class III or IV heart failure
	j)	Recent myocardial infarction or severe cardiac arrhythmias (within the past 6
		months)
	k)	Persistent uncontrolled hypertension despite medication use
	I)	An active, serious mental illness that reduces the ability to carry out Activities of
		Daily Living (ADLs) and would interfere with the patient's ability to operate the
		HNS and report problems to the attending provider.
	m)	Coexisting non-respiratory sleep disorders that would confound functional sleep
		assessment
	n)	Beneficiaries who are, or who plan to become pregnant.
	o)	Beneficiaries who require Magnetic resonance imaging (MRI) with model 3024.
	p)	Beneficiaries, who require Magnetic resonance imaging (MRI) with model 3028,
		can undergo MRI on the head and extremities if certain conditions and
		precautions are met. Please refer to the Manufacturer Guidelines for this model
		and future models for more information.
	q)	Beneficiaries who are unable or do not have the necessary assistance to operate
		the sleep remote.
	r)	Beneficiaries with any condition or procedure that has compromised neurological
		control of the upper airway.
The patient is	an appropriate	surgical candidate for anesthesia.
I declare that	I am certified by	the FDA approved manufacturer's second opinion service of validation.
		definition, is any documented conversation between an attending provider and the tiple providers. Providers shall provide these documents if requested by this
Date:	Tim	e: Provider Name:
Provider Signa	ature:	 